Wave Life Sciences 3Q 2026: Revenue $13.2M, Net loss $61.9M, EPS $(0.30) — 10-Q Summary

What happened

Wave Life Sciences reported third-quarter 2026 revenue of $13.2M, up 73% from $7.6M a year earlier, driven by GSK collaboration revenue. Net loss widened to $61.9M from $53.9M, while diluted loss per share narrowed to $(0.30) from $(0.32).

Confirmed

Global impact / market context

Revenue growth came from collaboration payments, not product sales, so the company still depends on partners and outside funding. The wider net loss means costs are rising faster than revenue, which increases the need for cash to fund trials.

Analyst inference

Investors in drug developers typically weigh cash needs against trial progress. Wave's upcoming filings and trial data could shape how the company funds research and whether it needs to raise more money or rely on partner payments.

Analyst inference

What to watch

1. Wave expects 600 mg multidose data for WVE-006 in the fourth quarter of 2026, after completing dosing across all trial cohorts and aligning with the FDA on a registrational trial. Confirmed
2. Wave plans to file a clinical trial application for its PNPLA3 candidate, WVE-008, in the fourth quarter of 2026, which is a request to regulators to begin human testing. Confirmed
3. Watch whether collaboration revenue and milestone payments keep covering rising costs, because a wider net loss may push Wave to raise more money or slow spending on early programs. Analyst inference

Evidence

• Original source link unavailable